CAPR - Capricor: Rolling BLA Submission Of CAP-1002 To Get DMD Treatment Program Going

2024-06-17 13:44:12 ET

Summary

• Capricor Therapeutics, Inc.'s rolling BLA submission of CAP-1002 for the treatment of patients with DMD, expected in Q3 of 2024.
• Top-line results from Cohort A of the phase 3 HOPE-3 study, using CAP-1002 for the treatment of patients with DMD, expected Q4 of 2024.
• Additional results from phase 2 HOPE-2 study, using CAP-1002 for patients with DMD, to be presented at the upcoming PPMD 30th Annual conference between June 27th - 29th of 2024.
• The global Duchenne Muscular Dystrophy treatment market size is expected to reach $8.19 billion by 2029.

Capricor Therapeutics, Inc. ( CAPR ) has a significant catalyst that is rapidly approaching, which could change the scope of this biotech. This would be regarding the release of top-line data from Cohort A of the phase 3 HOPE-3 trial, which is using CAP-1002 for the treatment of patients with Duchenne Muscular Dystrophy [DMD]. This isn't the only milestone for investors to look forward to, there are other opportunities expected throughout 2024.

The first of which would be that the company intends to release additional results from the phase 2 HOPE-2 OLE study, which is using this drug for the treatment of this patient population. Such results will be released at the upcoming Parent Project Muscular Dystrophy [PPMD] 30th Annual Conference, which is being held between June 27th to June 29th of 2024. This other data will hopefully lend additional credibility regarding the clinical data that has been released thus far. Lastly, there is another catalyst for consideration here, which, I believe, could also drive a further increase in shareholder value. This would be regarding the rolling Biologics License Application [BLA] submission of CAP-1002 for the treatment of patients with DMD in Q3 of 2024....

For further details see: